ReDI 2026: FDA Regulatory Strategies Conference Preview

Key Takeaways

• ReDI 2026 Conference will focus on innovative regulatory strategies for medical products.
• The conference will address FDA perspectives on drugs, devices, and biologics.
• Sessions will highlight clinical trial innovation and electronic submissions.

The Regulatory Education for Industry (ReDI) Annual Conference 2026, scheduled for May 19-20, 2026, will convene to discuss innovative regulatory strategies for advancing medical products. Hosted by the FDA, the conference will cover a range of topics, including advanced drug manufacturing, the application of artificial intelligence in drug development, and innovations in clinical trials.

ReDI 2026 is significant as a key forum for stakeholders to engage with FDA experts and learn about the latest regulatory updates and strategies. The conference aims to provide insights into navigating the evolving regulatory landscape for drugs, devices, and biologics.

ReDI 2026 Conference Overview

The ReDI 2026 Conference will take place on May 19-20, 2026. It will address FDA regulatory topics across multiple medical product areas. The agenda includes plenary sessions and presentations from FDA experts, offering a structured learning environment.

Key Presentations

The conference will feature a plenary session moderated by Brenda Stodart (Deputy Director, CDER), Michael Davis (Deputy Director, CDER), Owen Faris (Deputy Director, CDRH), and Katherine Szarama (Deputy Director, CBER). Introductions will be led by Captain USPHS Director, SBIA, DDI, OCOMM, CDER, with Kori Adair (Pharmacist, SBIA, DDI, OCOMM, CDER). These sessions will focus on the perspectives of various FDA centers.

Conference Schedule Highlights

Day 1 (May 19, 2026) will include a session on Clinical Trial Innovation, highlighting the activities and priorities of CDER’s Center for Clinical Trial Innovation (C3TI). Day 2 (May 20, 2026) will feature an FDA Electronic Submission Update, covering eCTD updates for v3.2.2 and v4.0, plus FDA information.

Market & Investor Implications

While the conference focuses on regulatory education rather than specific market-moving data, understanding FDA priorities and submission requirements is crucial for pharmaceutical, biotech, and medical device companies. Insights from ReDI 2026 can inform regulatory strategies and potentially streamline product development and approval processes.

What to Watch Next

Stakeholders should monitor the FDA website for further updates on the ReDI 2026 conference, including presentation materials and any post-conference reports. Tracking the implementation of C3TI initiatives and changes to eCTD requirements will be particularly important.

Frequently Asked Questions

• What is the focus of the ReDI 2026 Conference?

  The conference focuses on innovative regulatory strategies for advancing medical products, covering drugs, devices, and biologics.

• When and where will ReDI 2026 take place?

  The conference is scheduled for May 19-20, 2026.

• Who are some of the key speakers at the conference?

  Key speakers include Brenda Stodart (Deputy Director, CDER), Michael Davis (Deputy Director, CDER), Owen Faris (Deputy Director, CDRH), and Katherine Szarama (Deputy Director, CBER).

• What topics will be covered during the conference?

  Topics include clinical trial innovation, FDA electronic submission updates, advanced drug manufacturing, and the use of AI in drug development.

• Where can I find more information about the conference?

  Additional information can be found on the FDA website.

References

1. FDA. Regulatory Education for Industry (ReDI) Annual Conference 2026: Innovative Regulatory Strategies to Advance. https://www.fda.gov/news-events/regulatory-education-industry-redi-annual-conference-2026-innovative-regulatory-strategies-advance
2. FDA. ReDI 2026 Conference Schedule. https://www.fda.gov/media/192055/download